AC
ANRO icon

Almitas Capital’s Alto Neuroscience ANRO Stock Holding History

Almitas Capital’s Portfolio ANRO Stock Details ANRO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.77M Hold
78,520
– – 0.4% 49
2025
Q4 		$1.4M Sell
78,520
-116,625
-60% -$1.47M 0.31% 50
2025
Q3 		$784K Hold
195,145
– – 0.18% 50
2025
Q2 		$429K Sell
195,145
-39,241
-17% -$93.4K 0.11% 64
2025
Q1 		$506K Sell
234,386
-32,526
-12% -$116K 0.17% 60
2024
Q4 		$1.13M Buy
+266,912
New +$1.67M 0.25% 53

Other funds holding ANRO

AWG
Alpha Wave Global New York $791M AUM 113.77% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
SSC
Spruce Street Capital New York $416M AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Almitas Capital's ANRO Position: Q1 2026 in Review

Almitas Capital held its Alto Neuroscience (ANRO) position steady in Q1 2026 at 78,520 shares worth $1.77M. The position accounts for 0.4% of the portfolio, ranked #49.

Almitas Capital first reported a position in ANRO in Q4 2024 and has held it in 6 quarters since. 110 funds tracked by Wall St. Rank hold ANRO as of Q1 2026.

  • Almitas Capital held 78,520 shares of Alto Neuroscience worth $1.77M as of Q1 2026.
  • Almitas Capital left its Alto Neuroscience share count unchanged in Q1 2026.
  • Alto Neuroscience made up 0.4% of Almitas Capital's portfolio in Q1 2026, its #49 holding.
  • Almitas Capital first reported a position in Alto Neuroscience in Q4 2024 and has held it in 6 quarters since.
  • 110 funds tracked by Wall St. Rank held Alto Neuroscience as of Q1 2026.

Based on Almitas Capital's 13F filing for Q1 2026, filed 15 May 2026.